Clinical research on the combination therapy of vericiguat and metoprolol in the treatment of heart failure with reduced ejection fraction
- VernacularTitle:维立西呱与美托洛尔联合治疗射血分数降低型心力衰竭的临床研究
- Author:
Dandan LIU
1
;
Zhuoqun HE
2
;
Dan KOU
3
Author Information
1. Dept. of General Practice，Handan First Hospital，Hebei Handan 056000，China
2. Dept. of Emergency Medicine，Baoding No.1 Central Hospital，Hebei Baoding 071000，China
3. Dept. of Cardiology Ⅰ，Baoding No.1 Central Hospital，Hebei Baoding 071000，China
- Publication Type:Journal Article
- Keywords:
heart failure with reduced ejection fraction
- From:
China Pharmacy
2026;37(15):2030-2034
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To study the efficacy and safety of the combination therapy of vericiguat and metoprolol in the treatment of heart failure with reduced ejection fraction （HFrEF）. METHODS Prospective inclusion of 136 HFrEF patients admitted to the Handan First Hospital from January 2022 to January 2025， divided into a control group and an experimental group using a random number table method， 68 cases per group. At the same time as anti heart failure foundation， the control group was treated with metoprolol， while the experimental group was treated with metoprolol and vericiguat for 6 months. Compare the clinical efficacy and cardiac function indicators， serological related indicators， quality of life before and after treatment， and incidence of adverse reactions between the two groups. RESULTS Three cases were lost in the experimental group and four cases were lost in the control group. The total clinical effective rate of the experimental group was 95.38%， significantly higher than the control group’s 75.00% （P＜0.05）. Compared to before treatment， after treatment， the left ventricular end-systolic diameter， left ventricular end-diastolic diameter， homocysteine level， N-terminal pro-B-type natriuretic peptide level， C-reactive protein level， and Minnesota Living with Heart Failure Questionnaire scores of both groups of patients significantly decreased （P＜0.05）， while the left ventricular ejection fraction significantly increased （P＜0.05）， and the improvement effect of the experimental group was more significant than that of the control group （P＜0.05）. There was no statistically significant difference in the incidence of adverse reactions between the two groups of patients （P＞0.05）. CONCLUSIONS Compared to metoprolol alone， the combination of vericiguat and metoprolol can further improve heart function in HFrEF patients， better regulate serological related indicators， enhance quality of life and overall clinical efficacy， and has good safety.
